The growth of solid tumours proceeds through two distinct phases: the avascular and the vascular phase. It is during the latter stage that the insidious process of cancer invasion of peritumoral tissue can and does take place. Vascular tumours grow rapidly allowing the cancer cells to establish a new colony in distant organs, a process that is known as metastasis. The progression from a single, primary tumour to multiple tumours in distant sites throughout the body is known as the metastatic cascade. This is a multistep process that first involves the over-expression by the cancer cells of proteolytic enzyme activity, such as the urokinase-type plasminogen activator (uPA) and matrix metalloproteinases (MMPs). uPA itself initiates the activation of an enzymatic cascade that primarily involves the activation of plasminogen and subsequently its matrix degrading protein plasmin. Degradation of the matrix then enables the cancer cells to migrate through the tissue and subsequently to spread to secondary sites in the body.
Introduction
Mathematical modelling is now recognised as an important part of understanding complex biomedical systems. Although there are obvious limitations which must be recognised, mathematics does indeed have a contribution to make, at least in helping to understand the very basic building blocks of behaviour exhibited by the cell, the gene, or the enzyme.
This paper considers a mathematical model of the dynamics of cancer cell invasion of tissue, focussing on tissue degrading enzymes and the subsequent migratory response of cancer cells. Specifically we consider mathematical models in an attempt to understand certain properties and aspects of the urokinase plasminogen activation system and its role in cancer invasion and metastasis. It is clearly very difficult, if not impossible, model an entire biological system, and so to ask the question of what role a specific molecular component plays in effecting and/or controlling the locomotive behaviour of a cell leads immediately to a need to simplify or "deconvolute", in an appropriate and logical way, a highly complex biological system. Asking the next question of how to manipulate the effect of a specific component or to control its activity leads to the corresponding need to predict the outcome of a "reconvolution" of the system with altered properties. Last but not least, for the prediction of what will result from making any genetic or biochemical interventions targeting that component, it is necessary to integrate, or "reconstruct", the resulting alterations in the physical processes up to individual (stochastic) cell paths, and then finally up to cell population (deterministic) distributions.
With these points in mind, the modelling to be undertaken in this paper will focus on the level of cell populations or densities (as opposed to individual cells) and their response to concentrations of chemicals. With this initial modelling assumption a continuum approach is appropriate. Under the continuum hypothesis, the spatio-temporal state of a system of cells and/or chemical interactions is best described by partial differential equations (PDEs) derived from considerations of conservation of matter (see, for example, Ref. 107) . Assume that we have a fixed but arbitrary volume V enclosed by a smooth surface S and consider the flow of cells through this volume. The conservation equation states that the rate at which the number of cells changes (accumulates or disappears) within V must be balanced by the net flow (influx or efflux) of cells across the bounding surface S, plus the number of cells created (proliferation) or destroyed (cell death) within V , i.e.
where u(x, t) is the density of cells at position x and time t; J is the flux of cells through the closed smooth surface S = ∂V , per unit volume per unit time; K(u, p i ) describes the "population dynamics" of the cells, i.e. the proliferation and death of cells, and is generally described by a polynomial or rational function in u and p i ,
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where p i represent other variables (e.g. other cell types and/or chemicals) in the model. Using the divergence theorem, (1) may be written
Assuming the domain is fixed in time, we may differentiate through the integral. Using the fact that the choice of volume V was arbitrary, we have that at every point (x, t) the following conservation equation holds for our cell density u(x, t):
Similar equations may be derived for the other variables p i (x, t). Systems of the above form have been used to model a wide variety of biological phenomena and a number of examples can be found in the books by Murray 87 and Edelstein-Keshet.
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A more formal derivation of the equation can be found in Ref. 93 . Although over the past three decade or so a number of mathematical models have been proposed in an attempt to describe various key stages of tumour development, up till now the development of a basic "consensus" model of solid tumour growth and development is still a major challenge for mathematical biologists. In this regard, one of the major challenges of the next decade that mathematicians and modellers will face is to overcome Karlin's principle, namely: "The purpose of models is not (necessarily) to fit the data, but to sharpen the questions", 68 and develop biologically realistic mathematical models which, in addition to "fitting the data", can shed light on fundamental cancer processes ("sharpening the question"), in quantitative and predictive ways, thereby ultimately leading to an improvement in cancer treatment strategies.
Mathematical Modelling of Solid Tumour Growth and Invasion
In vivo cancer growth is a complicated phenomenon involving many inter-related processes. Solid tumour growth occurs in two distinct phases, the initial growth being characterised as the avascular phase, the later growth as the vascular phase. During the early avascular stage of solid tumour growth there may also be an immune response to the cancer from the host, with cells of the immune system (most notably T-lymphocytes) responding to and attacking the cancer cells. In some case, this may result in the complete eradication of the solid tumour by the immune system leading to the possibility of the development of a "cancer vaccination" as one possible treatment therapy. Unfortunately, solid tumours do not always remain avascular. The transition from avascular growth to vascular growth depends upon the crucial process of angiogenesis and is necessary for the tumour to attain nutrients and dispose of waste products. 54, 55 To achieve vascularization, tumour cells secrete a diffusible substance known as tumour angiogenesis factor (TAF) into the surrounding tissues. 56 This has the effect of stimulating nearby capillary blood vessels to grow towards and penetrate the tumour, re-supplying the tumour with vital nutrient. Invasion and metastasis can now take place. By the time a tumour has grown to a size whereby it can be detected by, in the case of breastcancer, simple self-examination, there is a strong likelihood that it has already reached the vascular growth phase. The primary aim of screening and the associated image enhancement technologies is therefore to detect cancers prior to this stage. For comprehensive reviews of the modelling in this area, see the excellent books of Adam and Bellomo, 1 Preziosi, 107 the work of Bellomo et al., 17 Szymańska, 118 Matzavinos et al., 81 Matzavinos and Chaplain, 82 and the review papers of Araujo and McElwain, 12 Mantzaris et al. 80 By contrast, tumour invasion is a relatively new area for mathematical modelling. However, over the last decade or so mathematical models of tumour growth and invasion have started to appear in the reasearch literature. Perhaps the first major papers in this area was the work of Gatenby and colleagues. Using analogies from population ecological mathematical models Gatenby 58 and Gatenby and Gawlinski 59 developed the first models of cancer invasion of tissue. In his initial paper Gatenby 58 used a Lotka-Volterra competition model to examine tumour biology through the dynamic interaction of malignant and normal cells. Furthermore, in his second paper, Gatenby and Gawlinksi 59 considered a deterministic reaction-diffusion equation model for cancer invasion. A reaction-diffusion model was developed describing the spatio-temporal distributions of tumour and normal tissue as well as H + ion concentration. The results of the mathematical model predict that high H + ion concentrations present in neoplastic tissue will penetrate, by chemical diffusion, as a gradient into adjacent normal tissue, where normal cells are unable to survive in this acidic environment and this results in a progressive loss of layers of normal cells and thus tumour invasion evolves. The paper by Orme and Chaplain 94 envisions a spherical tumour growing and invading with regard to the parent blood vessel vascularization which may consequently lead to metastasis. Their model describes the invasive tumour cells advancing towards the parent blood vessels (chemoattractants). However, capillary vessels were unable to reach some parts of the tumour (tumour centre) due to competition for space with tumour cells or high internal pressure which may cause vessels to collapse.
In the first of a series of papers, Perumpanani et al. 101 presented a theoretical model describing cell invasiveness as a function of tumour cell interactions with the local, normal host cells, noninvasive tumour cells, extracellular matrix proteins (ECM) and the proteases. Movement is described across a chemotactic/haptotactic gradient stimulus. Furthermore, their simulation studies demonstrated that the speed of invasiveness as well as the concomitant wave profile can be computed as a function of the tumour's phenotypic profile, its extracellular matrix make up, and the gradient stimuli the tumour finds itself in. In addition, their results highlighted the consequences of high protease production and excessive proteolysis of the extracellular matrix milieu in noninvasion. In a second paper, Perumpanani et al. 102 suggested that extracellular matrix-mediated chemotaxis runs in the opposite direction to that of invasion. Briefly, the idea behind this concept is that during the
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process of human fibrosarcoma cell line (HT1080) migration, they showed that the degraded components of the extracellular matrix exert a chemotactic pull stronger than that of undigested fragments and that this runs in the opposite sense, against the direction of invasion. In a more recent paper, Perumpanani and Byrne 103 investigated whether regional variations in extracellular matrix concentration affect the propensity of tumours to invade a particular tissue. In other words, they predicted that for the fibrosarcoma cell line (HT1080) both directed movement (haptotaxis) up a collagen gradient as well as HT1080 cell proliferation are related to a collagen gel concentration in a biphasic manner. Of particular note is their assumption that protease production is proportional to the product of the tumour cell density and collagen gel concentration, as a consequence of signals transduced in the invading cells by the surrounding exctracellular matrix milieu or the collagen gel.
Modelling of a related phenomenon, embryonic implantation involving the invasion of trophoblast cells into maternal uterine tissue, using a deterministic reactiondiffusion approach, has also been carried out. 25 A novel feature of their model is their assumption that trophoblast cells respond chemotactically to spatial gradients generated by the inhibitor, rather than the activator protease. Moreover, recently Byrne et al. 26 presented a simpler submodel of the aforementioned model, 25 carrying out a mathematical analysis and obtaining a typical travelling wave solution of the submodel.
More recently and with a departure from continuum modelling techniques, Anderson et al. 7 described a unifying conceptual theoretical framework for modelling tumour invasion and metastasis. They presented both deterministic and discrete approaches of describing the invasion of host tissue by tumour cells. The continuum approach examined the way that tumour cells respond to extracellular matrix gradients via haptotaxis in both one and two dimensions. In particular, the one-dimensional model simulations highlight the possibility that a small cluster of cancer cells can easily secede from the primary body of the tumour as a result of random and biased migration as well as matrix degrading enzymes. Furthermore, a pioneering contribution of the model lies in the fact that in their two-dimensional results they consider the medium in which the tumour grows to be heterogeneous. By introducing extracellular matrix heterogeneity, cells are no longer clearly amassed into those driven by haptotaxis and those driven by dispersion as a consequence of the already-existing gradients in the extracellular matrix. In addition, Anderson et al. 7 developed an extended discrete model using as a basis the aforementioned continuum model. The results of the discrete model confirmed the importance of haptotaxis (i.e. cell adhesion) for both invasion and metastasis and they also underscore the effect of cell proliferation in invasion and migration of cancer cells as an eventuality of its space-filling function. The implications of the model results for surgical resection of tissue were also discussed. These ideas have been subsequently extended by Anderson 6 where cell mutations are taken into consideration.
Another discrete modelling approach was adopted by Turner and Sherratt, 122 where a discrete model of malignant invasion was developed using an extension of the Potts model. 116 This model simulates a population of malignant cells experiencing interactions due to both homotypic and heterotypic adhesion while also secreting proteolytic enzymes and experiencing a haptotactic gradient. In this regard, they investigated the influence of changes in cell-cell adhesion on the invasion process.
In summary, we note that deterministic reaction-diffusion equations have been used to model the spatial spread of tumours both at an early stage in its growth 113 and at the later invasive stage 94, 59, 101 while modelling of related phenomena, i.e. embryonic implantation involving invading trophoblasts cells, using a reactiondiffusion approach has also been carried out.
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However, we would like to emphasise that all the models mentioned above (with the exception of Refs. 6 and 7) consider the medium (i.e. tissue, extracellular matrix) in which the solid tumours grow to be homogeneous. On the contrary, in vivo tissues have a high degree of fine-scaled spatial structure and the paper by Anderson et al. 7 investigates the important effects of spatial heterogeneity. In a similar vein, the work of Swanson et al. 119 considered tissue heterogeneity in the case of brain gliomas, which are generally highly diffuse. The impressive increased detection capabilities in computerised tomography (CT) and magnetic resonance imaging (MRI) have resulted in earlier detection of glioma tumours, although despite this progress the benefits of early treatment have been minimal. This is due to the fact that even after surgical excision well beyond the visible tumour boundary, regeneration near the edge of resection ultimately results. This is because the presently available imaging techniques only detect a small proportion of the actual, highly diffuse tumour. Experiments in rats show that malignant gliomas cells implanted in rat brain disperse more quickly along white matter tracts than grey matter. Swanson et al. 119 considered a simple reaction-diffusion model for glioma cell invasion on a two-dimensional anatomically accurate slice of brain tissue in which they imposed a spatially dependent cell diffusion coefficient to account for different cell motility rates in grey and white matter. Using numerical simulation, they characterised how the proportion of a tumour that was detected depended on the cell diffusion coefficients and the cell proliferation rate. They also showed that the heterogeneity within the brain caused the dynamics of tumour invasion to vary significantly depending on the initial location of the tumour. These results have important implications on how much tissue a surgeon should aim to remove when a tumour is detected (cf. Ref. 7) .
In the remaining sections of this paper we develop and analyse mathematical models of the urokinase plasminogen activation system, its role in tissue invasion, metastasis, tumour heterogeneity, and investigate its clinical implications. Cancer cell invasion is a very complex process and its understanding is facilitated by the understanding of the interactions of the plasminogen activation system components, as we will see in the following section.
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Biological Background
An overview of cancer
The word cancer is an "umbrella term" for approximately 200 diseases. Since the earliest medical records were kept, cancer as a disease has been described in the history of medicine. The origin of the word cancer is credited to the Greek physician Hippocrates (460-370 B.C.), considered the "Father of Medicine", who lifted medicine out of the realms of magic, superstition and religion. Hippocrates used the terms καρκινos (carcinos) and καρκινωµα (carcinoma) (the ancient Greek word for "crab") to describe a group of diseases that he studied, including cancers of the breast, uterus, stomach and skin. The hard centre and spiny projections of the tumours as well as the tendency of tumours to reach out and spread that Hippocrates first observed reminded him very much of "the arms of a crab", because of the way a cancer adheres to any part of its surroundings that it seizes upon in an obstinate manner like the crab does.
Besides the popular generic term "cancer " that the English language has adopted (which is also the Latin word for crab), there is another technical medical term for cancer: ν oπλασια (neoplasia). Neoplasia or neoplasm literally means new (ν˙ o) formation (πλασιs) in Greek. This indicates that cancers are actually new growths of cells in the body. In this regard the definition of a cancer is: "a new growth of tissue resulting from a continuous proliferation of abnormal cells that have the ability to invade and destroy other tissues". 69 Another term for cancer is "tumour". Tumour literally means "swelling" or mass. In this case, it refers to a mass of non-structured new cells, which have no known purpose in the physiological function of the body.
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At the early growth stage the tumour is relatively harmless and is still avascular, is it lacks its own network of blood vessels for supplying nutrients, including oxygen, and for removing wastes. 54, 55 The critical event that converts a self-contained pocket of aberrant cells into a rapidly growing malignancy comes when the tumour becomes vascularized. 55 That means that it has its own blood supply and microcirculation. A vascularized tumour has two distinct advantages over an avascular tumour:
(i) a direct supply of nutrients into the tumour. This results in a rapid increase in growth. (ii) the tumour can shed cells into the bloodstream.
Normal, as well as neoplastic, tissues become vascularized by a process called angiogenesis, the growth of new capillary blood vessels from pre-existing vessels. 54, 55, 19, 99 The first event of tumour-induced angiogenesis involves the secretion of a number of chemicals, collectively known as tumour angiogenic factors (TAF), into the surrounding tissue. 56 These factors diffuse through the tissue space creating a chemical gradient between the tumour and any existing vasculature. Upon reaching any neighbouring blood vessels, previously quiescent endothelial cells lining these vessels are stimulated to degrade their basement membrane, to invade the surrounding stroma and to migrate towards the tumour. As cells migrate, the endothelium begins to form sprouts which can then form loops and branches through which blood circulates. The whole process repeats forming a capillary network which eventually connects with the tumour, completing angiogenesis and supplying the tumour with the nutrients it needs to grow further. There is now also the possibility of tumour cells finding their way into the circulation and being deposited at distant sites throughout the body. 
Invasion and metastasis
Cancers also possess the ability to actively invade the local tissue and then spread throughout the body. Invasion and metastasis are the most insidious and lifethreatening aspects of cancer. 77, 78 Whether physiological or malignant invasion, the regulation for its necessary events involves spatial and temporal coordination, as well as certain cyclic "on-off" processes, at the level of individual cells. Motility, coupled with regulated, intermittent adhesion to the extracellular matrix and degradation of matrix molecules, allows an invading cell to move through the threedimensional tissue matrix. At the leading edge of the motile cell, receptor-ligand and proteolytic-antiproteolytic complexes coordinate sensing, protrusion, burrowing and traction of the cell.
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Conventional wisdom used to hold that invasion (as well as metastasis) is a late event -often "too late" -in the clinical course of a patient's cancer. However, it is now known that invasion can be both early and clinically "silent". 15 The threat of tumour invasion is exemplified by the fact that brain cancer does not need to metastasize to kill a patient. The growth of a brain tumour mass in the confined area of the skull causes compression damage: in addition, local invasion may enable brain tumour cells to move away from the primary tumour and to reach other sites within the brain. Such insidious behaviour may represent the inappropriate use of a programme responsible for the outgrowth of neuronal protrusions called neurites during normal neuronal development. 78 Indeed, cancer invasion in general may be a deregulated form of a physiological invasion process required for neuronal wiring in the embryo, tissue remodelling in the formation of blood vessels, and wound healing.
The most significant turning point in the disease (cancer), however, is the establishment of metastasis. The metastatic spread of tumour cells is the predominant cause of cancer deaths, and with few exceptions, all cancers can metastasize. At this stage, the patient can no longer be cured by local therapy alone. Metastasis is defined as the formation of secondary tumour foci at a site discontinuous from the primary tumour. 77, 78 Metastasis unequivocally signifies that a tumour is malignant and this is in fact what makes cancer so lethal. In principle, metastases can form following invasion and penetration into adjacent tissues followed by dissemination of cells in the blood vascular system (hematogeneous metastasis) and lymphatics Metastases can appear shortly after surgery but can also remain undetected for more than a decade before manifesting themselves clinically. 69, 31, 53 This indicates that disseminated cancer cells can persist in a dormant state, unable to form a progressively increasing tumour mass. 31 Such heterogeneity of outcome indicates that the fate of tumour cells that disseminate to distant organs before surgery must be regulated by either inherent cancer cell properties or the milieu of the target organs, or both. Identifying the mechanisms that keep metastases in their dormant, occult state is one of the most challenging and important avenues of cancer research.
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It is well recognised that the majority of cells within a tumour cannot complete the process of metastasis. Indeed, a very small percentage (0.01%) of circulating tumour cells entering the bloodstream successfully form clinically detectable lesions. 52 Thus, metastasis is a highly selective competition, favouring the survival of a minor subpopulation of metastatic tumour cells that pre-exist within the primary tumour. By inference, it follows that a similarly small percentage of cells within a primary tumour would display a marker for metastasis. 127, 46 A tumour marker can be defined as a substance produced either by a tumour or by the body in response to a tumour that aids cancer detection and/or monitoring. Just as it is easier to see a single, lit candle in a dark room than to find the only unlit candle in a room full of lit candles, it is easier to identify a single cell expressing a new metastatic marker against a background of non-expressing cells than it is to find non-expressing cells within a mass of cells that express a particular metastatic marker.
Proteolysis and extracellular matrix degradation
The prognosis of a cancer is primarily dependent on its ability to invade and metastasize. Many steps that occur during tumour invasion and metastasis (as well as in a number of distinct physiological events in the healthy organism, such as trophoblast invasion, and skin wound healing) require the regulated turnover of extracellular matrix (ECM) macromolecules. A more localised degradation of matrix components is required when cells migrate through a basal lamina. It is now widely believed that the breakdown of these barriers is catalysed by proteolytic enzymes released from the invading tumour. Most of these proteases belong to one of two general classes: many are metalloproteases, 97 while others are serine proteases. 10, 11 Proteases give cancers their defining characteristic -the ability of malignant cells to break out of tissue compartments.
However, proteolytic degradation of the extracellular matrix is essential for the processes of tissue re-modelling as well. These processes take place in a number of distinct physiological events in the healthy organism, such as trophoblast invasion, mammary gland involution, and skin wound healing. The plasminogen activation system has an important position among the extracellular proteases engaged in these degradation reactions. This system is organised as a proteolytic cascade with active proteases and their pro-enzymes, protease inhibitors, and extracellular binding proteins.
Although it was originally thought that their role was simply to break down tissue barriers, enabling tumour cells to invade through stroma and blood vessel walls at primary and secondary sites, it is now understood that matrix metalloproteinases (MMPs) and plasminogen activators (PAs) also participate in angiogenesis 99 and are selectively upregulated in proliferating endothelial cells. 30 In the following section, we will demonstrate the pleiotropic activities that the urokinase plasminogen activation system has in cell migration, cell movement, tumour progression, and metastasis. Rather than being comprehensive, the next section will cover specific areas which are currently undergoing rapid development.
The urokinase plasminogen activation system: Biology and regulation
Distant metastasis, and not the primary tumour itself, is the predominant cause of death in patients with malignant solid tumours. Thus, novel therapy concepts aimed at preventing tumour cell spread to distant organs are urgently needed. Up to now cancer drug development has focussed on the identification of molecules with cytotoxic activity against tumour cells. However, it has become evident that cytotoxic molecules, identified simply on the basis of their ability to poison as many cancer cells (and often, normal cells) as possible, are insufficient and, in some cases, undesirable to combat the progression of many tumours. In this regard, a paradigm shift is currently underway in the discovery of anti-cancer therapies focussing on the modulation of tumour characteristics other than tumour cell proliferation directly as a means of suppressing tumour growth, invasion and metastasis. These approaches include attempting to inhibit tumour neovascularization (angiogenesis), extracellular matrix (ECM) remodelling (e.g. during local invasion) and responsiveness of the tumour to growth factors as well as attempting to increase the rate of tumour cell apoptosis.
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Extracellular proteolytic enzymes such as serine proteinases and metalloproteinases, have been implicated in cancer invasion, angiogenesis and metastasis, the basic idea being that the release of proteolytic enzymes in tumours facilitates cancer-cell invasion into the surrounding normal tissue by breakdown of basement membranes and ECM (see the review by Mignatti and Rifkin 85 ). It has been suggested that plasminogen activation is an essential prerequisite to many of the activities mediated by tumour-associated cells and it has been implicated in angiogenesis, growth factor activation and mobilisation, ECM re-modelling, invasion and metastasis goes back several decades (see the review by Danø et al. 41 ). The serine proteases of the plasminogen activation system have traditionally been considered as part of the haemostatic mechanism owing to the dissolution of fibrin clots by plasmin (fibrinolysis). However, the plasminogen activation system has also been implicated in cellular migration, invasion and angiogenesis. 10, 11, 99, 100, 108 To some extent the existence of two distinct plasminogen activators accounts for these apparently distinct functions, with tissue plasminogen activator (tPA) being the primary fibrinolytic activator and urokinase-type plasminogen activator (uPA) the primary cellular activator which converts the proenzyme plasminogen to its active derivative, plasmin. Both plasminogen activators (PAs) are controlled by plasminogen activator inhibitors (PAIs), of which PAI-1 appears to be the predominant physiological inhibitor. Whereas tPA is primarily involved in clot dissolution (generation of plasmin for thrombolysis), uPA is recruited to the cell membrane immediately after its secretion via a specific uPA receptor (uPAR) expressed on the cell surface, and plays a role in localised cellassociated proteolysis which is an important process for cancer invasion, angiogenesis, tissue re-modelling, cardiovascular complications, wound healing, and the immune response. Thus, despite their common enzymatic activities, the two PAs appear to play distinct roles in the organism. Moreover, there are two main inhibitors of plasminogen activators, PAI-1 and PAI-2, while plasmin itself is inhibited by α 2 -anti-plasmin (α 2 AP).
The urokinase receptor (uPAR) is a cell membrane-anchored binding protein for uPA, accumulating plasminogen activation activity at cell surfaces. It has been claimed that binding of uPA to uPAR is required for its role in pericellular proteolysis because it would accelerate plasminogen activation, delay inhibition by PAI-1, regulate clearance of uPA, and localize plasmin proteolysis to the cell surface at the leading edge of the migrating cell.
Numerous studies have shown the relationship between the level of expression of uPA, uPAR, PAI-1 and their aggressive phenotypes of cancer. Based on evidence from experimental invasion and metastasis models and on expression patterns for components of the uPA system in tumours and normal tissues, it now seems beyond reasonable doubt that the uPA-mediated pathway of plasminogen activation plays a central role in tumour biology. In general, malignant tumours originating from the brain, colon, stomach, uterus, ovary, breast, kidney, colon and prostate express higher amounts or show higher activity of these enzymes than their normal or benign counterparts. 66, 120, 117, 86, 22, 57 Also more aggressive tumours show higher amounts of uPA system elements than less aggressive malignant tumours. Consequently, it has been established that in extensively investigated tumours such as breast cancers, the expression of uPA and PAI-1 can be used as prognostic markers predicting the outcome of the disease. 45 However, the uPA system appears to be involved not only in cancer cell migration and invasion, but also in other tumour processes which may collectively be called "cancer cell-directed tissue re-modelling". Examples of such processes are angiogenesis 100 and desmoplasia, i.e. stimulation of fibroblast proliferation and extracellular matrix protein synthesis. Although such processes involve migration and invasion by non-cancer cells, these may influence tumour growth, invasion and metastasis as well. Andreasen et al. 11 investigated such processes, and they have concluded that such a system has plasmin-independent functions, based on the interactions of PAI-1 and uPAR with integrins and the ECM protein vitronectin and of plasminogen activator-inhibitor complexes with endocytosis receptors. Nevertheless, this evidence was, to a large extent, obtained with non-cancer cells, but as has been stated in the previous section, no qualitative differences exist between cancer cells and normal cells (such as endothelial cells) with respect to the basic processes of migration and invasion.
In this regard, Danø et al. 42 pointed out the importance of the stromal/cancer cell interaction in cancer invasion, and of the "orchestration" of the various proteases in this complex process. In their view, cancer mimics specific tissue remodelling processes with invasion as a form of uncontrolled tissue re-modelling. Indeed, the same cell types that express specific components of the proteolytic system in re-modelling processes also do so in cancer invasion. In squamous skin cancer (as in skin wound healing), the epithelial or the cancer cells, in addition to macrophages, produce both uPA and uPAR. In colon cancer, as in the shedding of epithelial cells in gastrointestinal tract, uPA is produced by fibroblast-type cells, uPAR by cancer (or epithelial) cells, and PAI-1 by endothelial cells. In mammary cancer, as in mamary gland involution, uPA is produced by myofibroblasts, while uPAR is not produced by cancer cells but mostly by macrophages. For this reason, it is important to study the re-modelling processes of normal tissues in more detail.
In the following sections, we will describe the recent rapid increase in knowledge about the cell biology and regulation of plasminogen activation in relation to cell adhesion, tumour growth, cell migration, cell invasion and metastasis. Rather than being comprehensive, this section will cover specific areas related to the subsequent mathematical intrepretation of the plasminogen activation system in later chapters of this thesis. For a more detailed biochemical analysis of the model the reader is referred to the reviews by Andreasen et al., 10 Irigoyen et al. 64 and Andreasen et al. 
Roles and components of the PA system
Tumour expansion and dissemination can be considered as an unregulated tissue re-modelling process which progressively involves both cancer and normal cells. Recruitment and reorganisation of the normal host cells progressively impairs organ function, as neoplastic cells grow and influence the development of a supporting stroma infiltrated by a new blood capillary network. Tumour cell invasion and metastatic processes require the coordinated and temporal regulation of a series of adhesive, proteolytic and migratory events. Proteases have the potential to breach the mechanical barriers imposed by the basement membrane and surrounding extracellular matrix components, a prerequisite for endothelial, inflammatory or cancerous cell migration to distant sites. They have also been implicated in the activation of cytokines or other proteases, as well as in the release of growth factors sequestered within the extracellular matrix. Recent information has underlined the importance of cell-surface proteases, their receptors/activators or their inhibitors in cell migration, cell adhesion as well as in cancer cell invasion and metastasis. Novel information has recently been reported regarding the urokinase plasminogen activator system that underlines the importance of another signalling system in the mediation and regulation of cell recruitment and metastasis, although its role in extracellular matrix degradation goes back several decades (see the review by Danø et al. 41 ). This section will review the available information on the pro-metastatic activity of the uPA system, its regulation and the molecular mechanisms involved.
The enzymatic system consists of the urokinase receptor (uPAR), urokinase plasminogen activator (uPA), the matrix-like protein vitronectin (VN) and plasminogen activator inhibitors: type-1 (PAI-1) and type-2 (PAI-2). uPA is an extracellular serine protease produced from cells as a single-chain proenzyme pro-uPA. Two major functional domains make up the uPA molecule: the protease domain and the growth factor domain. The protease moiety activates plasminogen and, hence, generates plasmin, a serine protease capable of digesting basement membrane and extracellular matrix proteins. Plasmin itself is a broadly acting enzyme that not only catalyzes the breakdown of many of the known extracellular matrix (ECM) and basement membrane molecules, such as vitronectin, fibrin, laminin and collagens, but may also activate metalloproteinases. Thus, the unrestrained generation of plasmin from plasminogen by the action of plasminogen activator (PA) is potentially hazardous to cells. In this regard, the process of plasminogen activation in a healthy organism is strictly controlled through the availability of PAs, localised activation, and interaction with specific inhibitors (PAIs). One of these inhibitors, PAI-1, which is believed to be the most abundant, fast-acting inhibitor of uPA in vivo. 10, 11 In other words, for cells to protect themselves they must secrete a surplus of inhibitors to guarantee restraint of pericellular proteolysis. Indeed secreted uPA is often associated with plasminogen activator inhibitor-1 (PAI-1) and remains inactive.
The growth factor domain has no protease activity but can bind a specific, high affinity cell-surface receptor, uPAR (or CD87). uPAR is expressed in considerable amounts on the cell surface of various cell types and as implied by the name, it was first identified as a high-affinity receptor for uPA. Additionally, uPAR mediates the binding of the zymogen pro-uPA to the plasma membrane where plasmin converts pro-uPA to the active zymogen, uPA, which in turn converts plasma membrane-associated plasminogen into plasmin. Importantly, uPA is not the only ligand for uPAR that is able to bind to the matrix-like form of vitronectin (VN) and thus place emphasis on a non-proteolytic role for uPAR.
123,33 uPAR contains a vitronectin binding site(s) distinct from the urokinase binding site. The strength of interaction between uPAR and vitronectin is not mutually exclusive; rather inactive pro-uPA, as well as active uPA promote VN binding. In addition, uPAR can also bind integrins at sites distinct from its uPA-and vitronectin-binding sites. These interactions account for the effects of uPAR on cell adhesion and migration.
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At this point, the extracellular protein vitronectin enters the picture. Vitronectin is a versatile glycoprotein that is found in circulation, in the extracellular matrix of endothelial cells, and within various tissues of the human body. 96 Vitronectin participates in the regulation of humoral responses such as coagulation and fibrinolysis. Moreover, other functions of the protein that are confined to surfaces or tissues include cell-adhesion and regulation of pericellular proteolysis.
36 As the name indicates, vitronectin binds strongly to glass surfaces (vitro = glass). Interactions with an assortment of biological molecules are responsible for the multiple functions exhibited by vitronectin. Defining the binding sites for these various biomolecule, along with determining the molecular mechanism of regulation, constitutes an active area of research on the protein. Work to date has focussed on binding sites for several ligands, including heparin, plasminogen activator inhibitor-1, and integrins. Vitronectin binds several integrins expressed on the cell membrane, including α v β 3 . It accumulates prominently in extracellular matrices associated with acute injury and several malignant tumours. Vitronectin functions as the major high-affinity binding protein of plasminogen activator inhibitor type-1 (PAI-1) and urokinase plasminogen activator receptor (uPAR). The finding that uPAR contains a high affinity binding site for vitronectin may elucidate previously unexplained and paradoxical observations regarding this receptor.
First, these observations may account, at least in part, for the restricted cell surface localisation of urokinase-occupied uPAR to focal contact sites in fibroblasts. These contact sites are known to co-localise with vitronectin in adherent cell lines, and the presence of vitronectin has been shown to redistribute cell surface uPAR receptors. Second, these observations raise an alternative interpretation of the paradox that increased PAI-1 is associated with enhanced cellular movement, e.g. metastasis, even though this should decrease cell surface proteolytic activity.
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Vitronectin is recognised as the major binding protein of PAI-1, and its binding to uPAR could be expected to bring PAI-1 in close approximation with uPA, thereby promoting inhibition and clearance of uPA from the receptor. We postulate that this process may effect a lower avidity of cellular attachment to vitronectin. In this paradigm, PAI-1, although decreasing uPA activity, would also promote detachment of the cell from its contact site. Thus, PAI-1 in circumstances where sustained proteolytic activity is not vital to movement could promote rather than retard migration.
PAI-1, the inhibitor of uPA, belongs to the serpin (serine protein inhibitors) family 5 and can specifically bind to and inhibit not only free, but also receptorbound uPA. When PAI-1 is available, it can bind to the uPA/uPAR complex triggering the internalisation of the uPA/uPAR/PAI-1 complex by receptor-mediated endocytosis. The uPA/uPAR/PAI-1 complex will be dissociated and PAI-1 and uPA will be digested, but the receptor will be recycled to the cell surface and concentrate on the uPA (if available) on the cell surface again. This process will lead to clearing of PAI-1 from the vicinity of the cell surface. 92, 37, 38, 91 It is not clear why PAI-1 is concentrated in the nucleus of the cancer cell. However, many receptor-binding proteins bind to the receptor and are then endocytosed. It is, therefore, conceivable that such protein signalling (or their degradation products) acts directly within the cell, or cell nucleus. It has been reported that the receptor-mediated internalization of uPA/uPAR/PAI-1 complexes may trigger the proliferation of the cancer cells. Additionally, inhibition of cell adhesion and migration by PAI-1 on VN occurs because the same region of VN is required for interaction with PAI-1, uPAR and integrins. In other words, PAI-1 competes with uPAR for binding to VN.
The uPA/uPAR/PAI-1/VN system therefore appears to be a very important function in the regulation of the attachment/detachment machinery, namely to inform cells when, how and where to move. Availiable data suggests that cells respond to a "go" signal through the stimulation of surface proteolysis, exposure to chemotactic epitope(s), and recycling of "naked" uPAR to novel surface proteolysis, and to a "stop" signal via PAI-1-dependent internalization and degradation of uPA. Additionally, cells respond to a "pause" signal through transient uPARdependent adhesion stages, thus shifting the cells between an "adhesion-mode" and a "migration-mode". Thus occupation of cell surface uPAR by uPA and concomitant urokinase activity are ephemeral in the settings of this protease inhibitor.
Proteolytic stimulation of cell migration
Cell migration plays a central role in a wide variety of physiological and pathophysiological processes, for instance embryonal development, inflammation, and cancer metastasis (for reviews see Lauffenburger and Horwitz 75 ). Cell migration is the locomotion of a cell on a substratum of extracellular matrix (ECM) proteins. Cells require attachment sites on extracellular matrices in order to reorganise their cytoskeleton and initiate protrusions important to migration. In this regard, cancer cells require a well-regulated, pericellular proteolysis to migrate. They must cleave linkages to the extracellular matrix and to other cells and degrade barriers like the basement membrane, the destruction of which is a common observation in invasive cancer as well as in normal pathological situations such as wound healing.
Although proteolysis and migration through tissue barriers are normal cell functions in specific physiological circumstances, it is clear that a general aspect of malignant neoplasms includes a shift toward sustained invasive capacity. For invasion to take place, cyclic attachment to matrix components and subsequent release must occur in a directed and controlled manner. This implies that proteolysis, although enhanced in tumour cells, is still tightly regulated in a temporal and spatial fashion with respect to cell attachment. Proteolytic activity is the balance between the local concentration of activated enzymes and their endogenous inhibitors.
Cell migration proceeds through extension of the leading cytoplasmic edge, a process which among other events involves adhesion, mediated by several proteases and their extracellular matrix protein ligands. Such interactions lead to the generation of specific intracellular signals and reorganisation of the cytoskeleton. The adhesions at the leading cellular edge are thought to provide guidance and traction for pulling the cell body forward. Dissociation of integrin/ligand and cell surface receptor/ligand complexes, via regulated signals delivered from the cell interior, allows retraction of the trailing edge.
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This adhesion may not be so stringent as to prevent movement, nor too weak to provide traction. The extent of migration may thus vary with the avidity of adhesion. In addition, adhesion must be regulatable or reversible to allow detachment. Detachment from focal adhesive sites during migration is thought to occur by several mechanisms including cell surface proteolysis, alterations in integrin conformation, and bulk shedding of attachment sites. Extracellular proteolytic enzyme systems like the plasminogen activation system may facilitate release of the trailing edge by degradation of extracellular matrix proteins. Several proteases are involved in cell migration and invasion, but an important role has been ascribed to the plasminogen activation system.
The effects of the plasminogen activation system in cell migration may be due to a proteolytic as well as a non-proteolytic mechanism.
10,121 A proteolytic mechanism of cell migration implies plasmin generation at focal adhesion sites, catalyzed by uPAR-bound uPA, which could help to break physical barriers and promote detachment of the trailing edge of the cells from matrix proteins that might impede their migration. On the other hand, with a non-proteolytic mechanism, uPA is thought to promote cell migration by enhancing adhesion at the leading edge, through stimulation of binding of uPAR to VN, modulation of uPAR/integrin interactions and/or by initiation of signal transduction cascades.
125 It is also possible that both mechanisms operate simultaneously in migrating cells.
Soon after it was reported that uPAR contains a vitronectin-binding site, it was realized that active PAI-1 blocks the interaction of uPAR and vitronectin. In this regard, Waltz et al. 124 and Deng et al. 44 reported that PAI-1 regulates proteolytic activity (both on the cell surface and in solution), blocks binding of and adhesion to vitronectin by myeloid cells and also blocks binding of soluble uPAR (suPAR) -that is lacking the GPI-anchor -to vitronectin. Moreover, Kanse et al. 67 demonstrated that PAI-1 blocks binding of vitronectin to uPAR on endothelial cells. Inhibition of both uPA activity and of uPA/uPAR interactions prevents extracellular matrix degradation. On the other hand, when PAI-1 binds to vitronectin, it interferes with vitronectin recognition by integrins, thereby stimulating release of cells from the matrix and paradoxically supporting cell migration.
It seems possible to arrive at a model unifying the many observations by assuming that proteolytic and non-proteolytic mechanisms of uPA action on cell migration are operating simultaneously in individual migrating cells. If pro-uPA is converted to active uPA at the ventral surface of the cells, non-proteolytic mechanisms could dominate at the leading edge and proteolytic mechanisms at the trailing edge. The relative importance of the proteolytic and the non-proteolytic elements and the net effect of (pro-)uPA and PAI-1 would be expected to depend on the level of expression by the migrating cells of uPAR, endocytosis receptors, and integrins, of the composition of the ECM, of the pericellular localization of (pro-)uPA and PAI-1, of mechanisms for pro-uPA activation, and of the stimuli that induce cell motility.
Chemo-and hapto-taxis
Tumour cells encounter a variety of soluble and substratum-bound factors which may influence their directed migration at different stages in the process of tumour invasion and metastasis. Such factors can promote the directed movement of tumour cells by at least two mechanisms, termed chemotaxis and haptotaxis.
Chemotaxis is defined as cellular locomotion directed in response to a concentration gradient of a chemical factor in solution.
74 Cells sense the chemical and migrate toward higher concentrations of this substance until they reach the source secreting it. On the other hand, gradients do not have to be in solution. An adhesive molecule could be present in increasing amounts along an extracellular matrix. A cell that was constantly making and breaking adhesions with such a molecule would move from a region of low concentration to an area where that adhesive molecule was more highly concentrated. Such a phenomenon is called haptotaxis.
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The potential importance of a chemotactic response to ECM components is apparent when considering that during the process of tumour invasion and metastasis, proteolytic degradation results in solubilisation of ECM components.
76,13 As a result, tumour cells could conceivably detect and respond to the soluble fragments as well as to the insoluble intact matrix molecules. Therefore, chemotaxis and haptotaxis to ECM components represent two separate and distinguishable means by which tumour cells penetrate membranes and interstitial stroma.
Chemotaxis and signal transduction
Induction of chemotaxis and chemokinesis by uPA has been reported in a variety of cell types. 98, 60, 110 This activity is exerted through its specific, high affinity cell surface receptor uPAR (or CD87). 110, 61 This receptor is expressed by activated blood leukocytes, endothelial cells, macrophages, fibroblasts, and by different types of cells in human cancer. The receptor anchors uPA at the leading edge of migrating cells and localizes it at the focal contacts and to cell-to-cell contact sites. 20, 18, 51 These sites also contain adhesion molecules, integrins, cadherins, cytoskeleton-connecting proteins, and signal transducing molecules.
Cell motility (e.g. chemotaxis, chemokinesis, migration) stimulated by active uPA can involve plasmin generation and the subsequent degradation of ECM proteins and/or proteolytic trimming of cell surface components, including adhesion receptors and uPAR itself. uPAR has been reported to associate with many signalling molecules and to mediate signal transduction.
136,3,128 Much attention has been focused on the possibility that uPA binding uPAR activates intracellular signal transduction cascades. Recent reports observed that the binding of uPA to uPAR in tumour or endothelial cells activates the mitogen-activated protein kinases extracellular regulated kinase 1 and 2 (ERK-1, ERK-2). 90 However, a major question is how uPAR mediates cellular signalling, since uPAR is not a transmembrane molecule but belongs to the group of proteins that are tethered to the plasma membrane.
The membrane attachment of uPAR via a GPI anchor, i.e. the lack of an intracytoplasmic region capable of connecting with the cytoplasmic signal transducers, suggests the existence of one or more hypothetical "transmembrane adapter molecules" that connects uPAR and signalling molecules. 110 Integrins may serve as such signal transducers, and indeed uPAR has been shown to be associated in the plasma membrane with complexes of integrins and tyrosin kinases suggesting a role for these complexes in transmembrane transmission of signals via uPAR. uPA/uPAR interaction causes catalytically independent responses in endothelial cells, including chemotaxis and chemokinesis. Based on the fact that the binding of ligands to integrins initiates a signal-transduction cascade, it was speculated that the reported binding of uPA to the ligand VN is involved in initiation of a signal transducing cascade.
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Certain actions of uPA on different cell types in culture suggest that a signal is initiated by binding of uPA to uPAR. A chemotactic activity of uPA has long been recognized in vitro on different cell types in culture. 24, 60, 110 The chemotactic activity of uPA strictly depends on binding to its receptor uPAR: it does not occur in murine cells lacking uPAR, or containing uPAR but not recognizing human uPA; it can be restored by transfection of the uPAR; and it is inhibited by antibodies that prevent uPA/uPAR interaction. 110 Occupancy of uPAR transduces a signal that results in the movement of cells; indeed uPA binding to uPAR activates several tyrosine kinases. 24, 110 It is noteworthy that the signalling pathways activated by uPA/uPAR seem to be the same pathways that induce their own expression. Thus, it is possible that over-expression of the uPA/uPAR system in tumour cells leads to a signalling loop and/or activation of additional mechanisms dependent on these molecules that contribute to enhanced pericellular proteolysis, migration and proliferation.
3 However, at present the details of how uPA/uPAR/integrins interact and the precise way they assemble to generate signals are still under thorough investigation.
Cell adhesion and haptotaxis
Both cell-cell interactions and cell-stroma interactions play an important role during the invasive cascade. Connections through cell adhesion molecules, integrins, and cadherins stabilize tissue integrity, whereas loss or alteration of these cell surface proteins has been shown to be associated with increased metastatic potential. The strength and duration of cellular interactions are modulated by (a) the repertoire of receptor expression (especially integrins); (b) the relative abundance of adhesive and counteradhesive factors in the extracellular matrix; and (c) extracellular hydrolytic enzyme systems. In this regard, pericellular proteolysis initiated by the plasminogen activator/plasmin system fulfils pivotal functions in cellular migration. Direct binding of plasminogen activators and plasminogen/plasmin to cell surface receptors or to extracellular matrix drastically increases the local concentration and the efficiency of protease formation/action. The nonclassical activities of the plasminogen activation system and the pericellular cooperation of its components with adhesion receptors, extracellular matrix (ECM) proteins and signalling molecules, have provided new insights into their role as molecular coordinators of cell adhesion. The classical role of plasminogen activation is one counteracting cell-substratum and cell-cell adhesion, as pericellular plasmin generation leads to degradation of adhesion receptors and their extracellular matrix ligands. 85 However, under some conditions, binding of uPA to uPAR promotes cell-substratum adhesion. In this regard, binding of uPA to uPAR stimulates the adhesion of several integrinindependent cell lines to vitronectin (VN). On the other hand, PAI-1 inhibits uPARdependent adhesion to vitronectin. These observations show that uPA and uPAR may also affect cell adhesion. In addition, the avidity of uPAR for vitronectin is strongly promoted by occupancy of the receptor with uPA.
Recently, it has become clear that uPAR is involved in cell-stroma interactions and signal transducing events that are independent of its role in plasminogen activation. Both the expression pattern of uPAR and its proximity to adhesion and signalling molecules places this protease receptor at the crossroads of cellular adhesion. uPAR can be found at various locations depending on the cell type and activation state. 71 For example, it can be found at the apical surface of quiescent epithelial or endothelial cells or concentrated at focal or cell-cell contacts in invasive cells in association with other proteins, such as ECM adhesion molecules, cytoskeletal elements, integrins and signalling factors. It participates in cell adhesion directly by binding to vitronectin and indirectly by modulating the affinity of integrins for their complementary ligands.
105
uPAR has been shown to bind not only uPA, but also the extracellular matrix protein, vitronectin (VN). By virtue of the latter activity, it acts as an adhesion receptor. 125 The vitronectin-binding site on uPAR is distinct from the uPA binding site. The vitronectin/uPAR complex is enhanced by the simultaneous binding of urokinase. 125, 67 The uPA/uPAR interaction increases the binding of vitronectin to the cells meaning that, somewhat paradoxically, uPA promotes cell adhesion. In this regard, it has been proposed by Wei et al. 125 that the interaction of uPAR binding to vitronectin takes part in a balanced attachment and release scenario, directed by the plasminogen activator inhibitor type-1, which competes with uPAR in the vitronectin binding process.
44
A further, indirect role of uPAR in adhesion is provided by interactions with certain integrins, influencing the binding properties of the latter. 125, 121 This broadens the currently held concept of uPAR-integrin interactions, in which uPAR is proposed to interact exclusively with integrins residing on the same cell (cis interaction) as an "associated protein" that mediates signal transduction directly or through the mediation of a distinct transmembrane adaptor protein. The simultaneous recognition of vitronectin by uPAR and integrins co-localizes these two receptors to adhesion structures and directs (haptotaxis) the proteolytic activity of plasminogen systems to the matrix.
Likewise, to make matters even more complicated, active PAI-1, which is the main PA antagonist, serves as a potent competitor for vitronectin binding to uPAR and integrins and thus disrupts uPAR-mediated adhesion, but also sterically inhibits integrin binding to vitronectin. Vitronectin is considered the primary PAI-1 binding plasma protein. Like PAI-1, vitronectin is significantly increased at sites of disease, or injury, where it binds collagens, uPAR or integrins. PAI-1 also seems to play a central role in cell adhesion mediated through integrins or the uPA/uPAR complex. However, when PAI-1 inhibits uPA or when PAI-1 binds vitronectin, the uPA/uPAR complex no longer interacts with vitronectin. The higher affinity of PAI-1 to vitronectin than that of the uPA/uPAR complex to vitronectin is likely to be responsible for the release of cells from this substratum by an excess of PAI-1.
40
Therefore Deng et al. 44 suggested that the delicate balance between cell adhesion and cell detachment is governed by PAI-1. It is tempting to speculate that the de-adhesive effects of PAI-1 are related to the observation that high PAI-1 levels are associated with a poor prognosis for survival in several metastatic human cancers.
7
All studies on the PA-plasmin system cited in this section provide ample evidence for the requirement for this system in a large number of biological phenomena and in a variety of diseases. Cell migration, cell adhesion, angiogenesis, cancer invasion and metastasis, etc. seem too many, and the underlying mechanisms and functions too different, for one protease with a single substrate, plasminogen. The recent results on signal transduction show that uPA, in addition to its enzymatic activity, can signal through its receptor inducing a variety of activities which liken it to chemokines. The assimilation explains uPA pleiotropism and its involvement in so many different diseases.
The original idea of plasminogen activation as a rate-limiting factor in tumour invasion and metastasis has been supported by many results with in vitro and in vivo model systems and by demonstration of correlations between patient prognosis and tumour levels. The increased knowledge about the system has also led to the realization that the system works in a far more complex way than described by the original hypothesis. Much evidence suggests that the system also has plasminindependent functions, consisting in intracellular signal transduction cascades being initiated by binding of uPA to uPAR, in uPAR acting as a vitronectin receptor and as a regulator of integrin function, in PAI-1 acting as a regulator of uPAR and integrin binding to vitronectin, in interactions with endocytosis receptors and in an interplay with other proteolytic enzyme systems.
This linkage suggests to us that four molecules: uPA, PAI-1, uPAR and vitronectin, constitute the core of an integrated dynamical system which allows spatial and temporal rearrangements of its components at cell surfaces during cell migration and invasion. Moreover, it has become clear that the system has a multifunctional role in tumour biology. The system seems to function not only in cancer cell migration and invasion, but also in re-modelling of the tissue surrounding the cancer cells, which may contribute decisively to the overall process of metastasis. As the biologies of individual tumours are different, different processes may be rate limiting for the endpoint of metastasis in different tumours, and the importance of the uPA system may therefore vary.
The Mathematical Model of Proteolysis and Cancer Cell Invasion of Tissue
In this section we develop and analyse a new mathematical model of cancer cell invasion of tissue, based on an explicit consideration of plasmin production, and we investigate how interactions between cancer cells, urokinase plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1), plasmin and the extracellular matrix substrate (ECM, or a component of ECM such as vitronectin) may regulate tumour invasion and metastasis. As we have described in the previous sections, plasmin is a protease which is generated at the cell surface from its inactive precursor, plasminogen, via the proteolytic activity of urokinase-type plasminogen activator (uPA). In addition to fibrin and other proteases, plasmin cleaves many extracellular matrix proteins, including fibronectin, laminin, vitronectin and thrombospondin and can activate many of the matrix metalloproteinases, which still degrade other matrix constituents. Plasmin can also affect the activity of cytokines and growth factors, notably TGF-beta, which influences the composition of the extracellular milieu. In this regard, the unrestrained generation of plasminogen activator (uPA) is potentially hazardous to cells. Therefore, to maintain tissue homeostasis and avoid unrestrained tissue damage, plasmin activity must be tightly controlled. Such regulation is achieved at multiple "checkpoints" within the plasminogen system. A primary role in plasmin regulation is played by the availability of the plasminogen activators and their corresponding inhibitors.
In what follows, we denote cancer cell density by (c), urokinase plasminogen activator (uPA) concentration by (u), plasminogen activator inhibitor-1 (PAI-1) concentration by (p), plasmin concentration by (m) and the extracellular matrix substrate (ECM, vitronectin) density by (v). We consider the following fundamental biological interactions that are known to occur during the invasion process:
Cancer Cells: When considering the evolution equation of the cancer cell density, the dominant factors governing the cancer cell locomotion are random motion, chemotaxis due to urokinase plasminogen activator (uPA) 18 Additionally, we include a proliferation term. Therefore, based on the above assumptions we obtain the "word equation" below for the cancer cell density:
(rate of change of cell density) = (random motility) − (chemotaxis due to uPA) − (chemotaxis due to PAI-1)
+ (haptotaxis due to VN) + (proliferation) + (extra proliferation due to uPA -cancer cells interactions).
Assuming a one-dimensional spatial domain and representing by D c , χ c , ζ c , ξ c , µ 2 and φ 13 the random motility, uPA-mediated chemotaxis, PAI-1-mediated chemotaxis, VN-mediated haptotaxis coefficients, the cancer cell proliferation rate and the cancer cell-surface receptors recycling rate respectively, then the above "word equation" takes the following mathematical form:
Regarding cell proliferation, we assume that cancer cell proliferation satisfies a logistic growth law, with µ 1 representing the proliferation rate and c o representing the maximum sustainable cell density for cancer cells. A similar model assuming competition for space between the cancer cells and the extracellular matrix is considered by Lolas. 79 The differences between the results of the two models are not significant.
Additionally, we include the (φ 13 cu) term representing the fact that uPA "augments" cell proliferation in physiological 104 and pathophysiological processes.
96,4
It is assumed that the binding of uPA to its cell surface receptor (uPAR), forms the uPA/uPAR complex which additionally is able to bind to PAI-1 and form the resulting uPA/uPAR/PAI-1 complex. [9] [10] [11] The resulting uPA/uPAR/PAI-1 complex is internalized and degraded. Consequently, uPAR is internalized as a component of the complex uPA/uPAR/PAI-1 and then co-endocytosed but later re-circulated to the cell surface. The re-circulated cancer cell surface receptor gives the cell the opportunity to bind to VN and other extracellular matrix components that are also assumed to enhance cell proliferation. Furthermore, another approach is that uPA bound to cancer cell-surface receptors triggers several transducing signals that promote cancer cell proliferation as well.
Extracellular Matrix: It is known that ECM does not diffuse and therefore we omit any diffusion terms (or other "migration" terms) from its behaviour. In addition, based on the experimental evidence that uPA activates plasminogen to produce the cancer cell-surface associated protein plasmin which in turn catalyzes the breakdown of many of the known extracellular matrix (ECM) and basement membrane molecules (such as fibronectin, laminin, vitronectin and collagen) we assume that plasmin formation either degrades the extracellular matrix upon contact or through its activation from uPA secretion. 64 Moreover, several studies suggest that normal cells, as well as cancer cells such as gliomas, have the ability to produce numerous ECM components. 43 On the other hand, as has previously been mentioned, the major role of PAI-1 is to inhibit uPA production and thus we assume that PAI-1 binding to uPA results indirectly in the production of VN (vitronectin). In other words, we assume that uPA binding to PAI-1 releases the PAI-1-bound VN and therefore gives VN the opportunity to bind to the cell-surface receptors such as uPAR and/or integrins and promote its own production through the regulation of cell-matrix-associated signal transduction pathways. Finally we assume a logistictype proliferation or re-modelling term for the extracellular matrix.
Incorporating all these terms, we obtain the following "word equation":
(Rate of change of ECM density)
= −(degradation due to plasmin formation) + (proliferation) + (indirect growth of VN due to PAI-1/uPA binding)
− (neutralization due to PAI-1 inhibition).
Denoting by, δ the degradation rate, µ 2 the proliferation rate, φ 21 the production rate of PAI-1/uPA binding, and φ 22 the counterbalancing of PAI-1 binding to VN, we can write the "word equation" as the following equation:
where v o represents the maximum sustainable density for the extracellular matrix.
Urokinase plasminogen activator -uPA: The evolution of the concentration of the urokinase plasminogen activator (uPA) (secreted by the cancer cells and acting as a chemoattractant) is assumed to occur through diffusion driving its motion, cancer cells acting as sources, while its binding to PAI-1 as well as to cancer cell surface receptors dominates its removal from the system. Combining these assumptions yield the following "word equation":
(Rate of change of uPA concentration) = (motion due to diffusion) + (production due to cancer cells) − (removal due to PAI-1 inhibition)
− (removal due to binding to cancer cells).
If we denote by D u , α 31 , φ 31 and φ 33 respectively, the uPA's diffusion coefficient, its rate of production by cancer cells, its neutralization by PAI-1 inhibition and its rate of binding to cell-surface receptors (uPAR), then the above word equation can be rewritten as:
Plasminogen activator inhibitor-1: The plasminogen activator inhibitor-1 (PAI-1) conservation equation is similar to that of uPA considered above. Thus, diffusion drives its motion, while it is either produced as a result of plasmin activation or through direct secretion by the cancer cells and is counterbalanced by its binding to VN and uPA respectively. Regarding the aforementioned assumptions we obtain the "word equation" below:
(Rate of change of PAI-1 concentration) = (motion due to diffusion) + (production due to plasmin activation or cell secretion) − (loss due to VN binding) − (loss due to uPA binding).
Denoting by D p the PAI-1 diffusion coefficient, α 41 the rate of production as a result of plasmin formation, φ 41 the neutralization rate by uPA binding and by φ 42 the neutralization rate by VN binding, then the above word equation can be rewritten as:
Plasmin: In examining the conservation of mass regarding plasmin concentration, we assume that binding of uPA/uPAR provides the cell surface with a potential proteolytic activity via activation and cell-surface co-localization of plasminogen and thus enhances rates of plasmin formation, 10, 33, 11 while the activity of uPA, and therefore the formation of plasmin, is inhibited by the binding of the serine protease inhibitor-1 (PAI-1) to urokinase plasminogen activator (uPA). 37, 38, 10, 33, 11 In addition, we assume that the binding of PAI-1 to VN indirectly results in the Denoting by D m , φ 53 , φ 52 and φ 51 , respectively, the plasmin diffusion coefficient, its rate of production due to uPA/uPAR binding, its rate of production due to PAI-1/VN, and its inactivation rate due to uPA inhibition by PAI-1, then we have:
Hence the complete system of equations describing the interactions of cancer cells, ECM, uPA, PAI-1 and plasmin is: 
Dropping the tildes for notational convenience, we obtain the non-dimensional system of equations:
In order to close the system, boundary and initial conditions, for c, v, u, p and m are required.
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Boundary Conditions: We impose zero-flux boundary conditions for all the variables of the model at x = 0 and x = 2.
Initial Conditions: The initial distribution of the tumour cells, the extracellular matrix density, the urokinase plasminogen activator (uPA), the plasminogen activator inhibitor-1 (PAI-1) concentration and the plasmin concentration are prescribed by the system of equations (11). Initially we assume that there is a cluster of cancer cells already present and that they have penetrated a short distance into the extracellular matrix while the remaining space is occupied by the matrix alone.
In addition, we assume that the uPA protease as well as the PAI-1 (inactivated) inhibitor initial concentration are proportional to the initial tumour density while we assume that the plasmin protease is not yet produced from the cancer cells.
Combining the above we have the following system,
where throughout the paper we have taken ε to be 0.01.
Estimation of parameters
Before proceeding with numerical simulations of the system (10) with appropriate initial conditions (11) However, regarding the existence of uPA as well as PAI-1, we believe that the plasmin diffusion coefficient will be much smaller. Therefore we choose the dimensionless parameter D m to be in the range of 4.91 × 10 −2 -4.91 × 10 −4 .
Yu et al. 129 estimated the doubling time of human epidermoid carminoma cells (HEp3) from in vitro proliferation experiments time to be 24 h. However, small differences in growth rate were observed but they did not bear a relation to the level of the urokinase plasminogen activator receptor (uPAR). In contrast, HEp3 with a full uPAR complement grows best when crowded. By taking the proliferation rate as the reciprocal of the cell-cycle time we getμ 1 35 Naski et al., 89 Andreasen et al. 10 we assume that the reference concentrations of PAI-1, VN and uPA have nanomolecular values, O(10 −9 M) ≡ 1 nM. In addition, Ries et al., 109 as well as Ellis 49 in their experiments have used plasmin concentration of 0.5 nM and 100 pM respectively. Therefore, we assume that plasmin has a reference concentration of 0.1 nM which is in agreement with the nanomolecular concentrations that we used for PAI-1, VN and uPA. Along with the results of Stokes et al., 114 we choose the dimensionless parameter values for the chemotactic and haptotactic coefficients, namely χ c , ζ c , ξ c to vary between 0.001-1, the parameters φ 21 , φ 31 , φ 51 to vary in the range of 0.1-1 and φ 22 , φ 42 , φ 52 in the range of 0.1-1.
There were a number of parameters in the model that we were unable to estimate. In this regard, these parameters were chosen in order to give the best qualitative results. Regarding the secretion rates of uPA from the cells as well as the secretion of PAI-1 from cancer cells or through plasmin formation, we choose the following dimensionless values for our parameters, α 31 = 0.1-2 and α 41 = 0.1-2. In addition, for the terms φ 13 , φ 33 , φ 53 which actually represent functions associated with the uPA binding to the cell surface receptors, such as uPAR and integrins, in other words the proliferation rate of cells due to uPA-binding to the cell surface receptors complex (as in φ 13 ), the neutralization rate of uPA (as in φ 33 ) and the production (activation) rate of plasmin (as in φ 53 ). In this regard, by considering the dissociation constant of uPA bound-uPAR to be in the range of 0.1-0.5 nM 10, 50 and additionally taking the uPAR concentration to be in the subnanomolar range, i.e. 0.4-23 nM 48 then we can choose φ 33 , φ 53 to be in the range of 0.1-1. However, regarding φ 13 which represents the cancer cells proliferation rate due to uPA binding to the cell-surface receptors we were unable to find experimental data associated with the aforementioned parameter. Therefore, lacking experimental data for the indirect and through signalling regulated cancer cell proliferation rate we choose φ 13 to have a value between 0.01-1. In the absence of any experimental results associated with the degradation rate of the extracellular matrix we choose the dimensionless parameter for δ to vary between 1-20.
Numerical Simulation Results
The system of equations (10) was solved using the D03PCF routine available from the NAG library which integrates systems of parabolic partial differential equations using the method of lines and Gear's method. Full details can be found in Lolas.
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A discussion of the general spatio-temporal dynamics of the model will be given in the last section of the paper along with an indication of the mathematical analysis which can be carried out on the system (cf. Lolas 79 ). In this section we will confine ourselves to describing the results of the model for a given set of parameter values and the implications of the results as they impact on the underlying biology of cancer cell invasion of tissue. The time-plots of the profiles of the variables of system (10) shown in the figures in this section were obtained using the following set of parameter values (unless otherwise specified): From the results presented in Fig. 1 , we note that by t = 1 (∼ 3 hours) a group of cancer cells has built up at the leading edge of the primary tumour. By t = 25 (∼ 3 days), cancer cells start to produce more uPA which in turn activates plasmin and therefore degrades the ECM. As time evolves, at t = 35 (∼ 4 days) two distinct cluster of cells have formed: one near the left-hand boundary and the other one at the centre of the plot as a consequence of increased cancer cell proliferation. By t = 55 (∼ 6.5 days) the previously central cluster of tumour cells starts to migrate driven mainly by VN-mediated haptotaxis. In addition, by t = 60 (∼ 7 days), in Fig. 2 , new clusters of cells have formed. By t = 105 (∼ 9 days) three main groups of cancer cells have formed with regions of extracellular matrix re-establishment due to re-modelling also observed. As time evolves, at t = 125 (∼ 14.5 days) the "anarchy" that characterizes the proliferating heterogeneity of solid tumours is observed and more clusters of cancer cells are forming while others are migrating further into the domain. At t = 150 (∼ 17.5 days) more cluster of cells have generated due to unrestricted cancer cell proliferation. At t = 165 (∼ 19 days), in Fig. 3 , the generation of more groups of cancer cells is observed, while by t = 185 (∼ 21.5 days) the dynamic spatial heterogeneity of the cancer cells is even more evident and we can note several groups of cancer cells accompanied either by extracellular matrix re-distribution or by increased levels of urokinase plasminogen activator (uPA) concentration. By t = 250 (∼ 29 days), six clusters of cancer cells have formed, with groups migrating to both boundaries of the domain driven by hapto-or chemo-taxis respectively. Additionally, by t = 310 (∼ 36 days) we note a re-distribution of the extracellular matrix components accompanied by a decrease in the number of cancer cell clusters. Furthermore, we note that the rapid extracellular matrix re-establishment observed at t = 310 (∼ 36 days), in Fig. 4 , is followed by a substantial increase of new cancer cells clusters throughout the domain. By t = 410 (∼ 47.5 days) we observe five main clusters of cancer cells, while by t = 450 (∼ 52 days) we see six clusters of cells. Finally, at t = 500 (∼ 58 days) we observe a rapid extracellular matrix renewal in regions where there are lower densities of cancer cells together with a rapid increase in tumour cell cluster formation.
In the next set of figures, we examine the relative importance of the preferential binding of the inhibitor PAI-1 to VN (i.e. the matrix) rather than uPA in the model. Therefore, we consider the parameter values φ 22 = φ 42 = 0.55 > φ 21 = φ 31 = φ 41 = φ 51 = 0.15. We also make the simple assumption that the aforementioned preferential PAI-1 binding to VN will also result in the increase of uPA binding to the cell-surface receptors and consequently in the increase of plasmin production and choose φ 52 = 0.55 (all other parameters as in Fig. 1 ). With the above described changes we produce the sequence of plots in Figs. 5 to 7. At t = 10 (∼1 day), in Fig. 5 , cancer cells migrate into the domain driven mainly by haptotaxis, while at t = 25 (∼ 3 days) the cells have migrated more than halfway through the domain. This is due to the fact that cancer cells start to produce more uPA as they approach the "protected" extracellular matrix containing the inhibitor. In addition, this will result in release of VN and in uPA/PAI-1 binding and/or the formation of cancer cell-surface receptors-uPA-PAI-1 synthesis. Therefore, by t = 55 (∼ 6.5 days) we note that cancer cells have migrated through/across the entire domain. This is due to the fact that although the initial role of PAI-1 is to protect extracellular matrix from excessive proteolysis its presence can also result in the regression of extracellular matrix re-establishment and its signalling effects with cancer cell interactions. By t = 60 (∼ 7 days), in Fig. 6 , two small cluster of cells start to form, while by t = 80 (∼ 9 days) these previously distinct groups of cells have joined to form a large band of cells while their motion is driven by uPA and PAI-1 mediated chemotaxis. At t = 105 (∼ 12 days), four distinct clusters of cells have formed, although at t = 125 (∼ 14.5 days) only one group of cells is present accompanied paradoxically with decreased levels of PAI-1. At t = 150 (∼ 17 days) the previously described group of cancer cells starts to migrate towards the left-hand boundary as a result of increased PAI-1-directed chemotaxis. It is worth noting that the aforementioned plots were accompanied with increased PAI-1 presence. This is the result of the extracellular matrix degradation that additionally leads to PAI-1 release and its increased presence. As time evolves, at t = 185 (∼ 21.5 days) in Fig. 7 , four distinct clusters of cells have formed, while at t = 225 (∼ 26 days) most of the clusters of cells have migrated to either boundary while also decreased levels of PAI-1 were present. By t = 250 (∼ 29 days) this group of cancer cells starts to migrate towards the right-hand boundary. Furthermore, at t = 310 (∼ 36 days), several clusters of cells have formed as a result of increased PAI-1 presence. The results of these numerical simulations give a predictive insight into the "dynamic activity" which may occur during solid tumour growth and are in agreement with experimentally and clinically observed cancer cell proliferative heterogeneity and paradoxically PAI-1 invasive promoting function.
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In the following set of Figs. 8 to 10 we assume that the binding rates of uPA, PAI-1 and VN (parameters φ 21 , φ 31 , φ 41 , φ 51 By choosing the aforementioned parameter values we make the simple assumption that there is a competition for binding between the uPA, PAI-1 and VN since we consider similar values for the parameters that describe their interactions. In addition, we also make the simple assumption that the dominant taxis effect is due to a response to uPA concentration gradients rather than either PAI-1 gradients or VN gradients (i.e. χ c > ξ c > ζ c ). Based on the above assumptions, we note that at t = 1 (3 hours), in Fig. 8 , a large cluster of cells has built up at the leading edge of the primary tumour. However, by t = 10 (∼ 1 day) due to the "taxis" competition between uPA, PAI-1-mediated chemotaxis and VN-mediated haptotaxis respectively, the cancer cells are unable to migrate further at this time. However, by t = 35 (∼4 days) the cancer cells that are situated slightly ahead of the established large grouping of tumour cells start to produce increased levels of plasmin that results in the local degradation of the substratum components. Therefore, by t = 55 (∼ 6 days) only a small group of the large cluster of cancer cells has migrated a small distance into the domain, but this small group is capable of producing plasmin that degrades the extracellular matrix far ahead of the primary tumour position. In addition, we observe increased levels of PAI-1 production far ahead of the leading front in order to counterbalance the uncontrolled plasmin regulation. By t = 60 (∼ 7 days), in Fig. 9 , we note the formation of several clusters of cells as a result of their uncontrolled proliferation. However, there is a lack of cancer cell migration due to gradient competition between PAI-1-mediated chemotaxis and VN-regulated haptotaxis. At t = 70 (∼ 8 days) cancer cells have migrated further into the region while by t = 105 (11 days), more clusters of cells have formed due to their proliferation. Additionally, by t = 125 (∼ 14.5 days), several groups of cells are observed while regions of extracellular matrix re-establishment are noted. Furthermore, at t = 180 (∼ 21 days), in Fig. 10 , we point out regions of extracellular matrix redistribution together with an increase in the cancer cell groupings. Although the simulations are presented up to a time of t = 250 (∼ 29 days), longer time simulation results (not presented here) were carried out and it was found that the multiple clusters of cancer cells appeared to persist indefinitely in a dynamic fashion.
Having examined the spatio-temporal dynamics of the model for a range of parameter values and having focussed on some different effects, such as differential binding rates, we now consider several changes in the model in order for us to examine the system behaviour by the inclusion or the exclusion of various other terms such as by cancer cell apoptosis as well as an indirect cell proliferation. To this end we will assume that since the uPA-binding to cancer cell surface receptors results in both having a proliferative influence over the tumour's behaviour and an activating effect in the production of plasmin, we consider that over-production of plasmin is a signal for cancer cell apoptosis. 10, 11 This is achieved by including a term −ω 1 m in the cancer cell equation.
Additionally we assume that the PAI-1 binding to VN will result in indirect cancer cell proliferation since it will eventually activate uPA-cancer-cell surface binding, and include a term φ 14 pv in the cancer cell equation. Finally, we consider that vitronectin binding to the cancer cell surface receptors will result in a further plasmin decrease, as a result of uPA occupation by PAI-1, and include an extra term −φ 54 cv in the plasmin equation to reflect this. Therefore, the modified system that we will now consider takes the following form:
To close our system once again we take our initial conditions to be given by Eq. (11) with zero flux boundary conditions.
We first consider the relative importance of uPA production in excess of PAI-1 production (i.e. α 31 = 0.75 > α 41 = 0.25) with an increased uPA-cancer cell binding (φ 13 , φ 33 = φ 53 = 0.5) which will then result in increased plasmin formation as well as increased uPA neutralization.
Considering the aforementioned changes we obtain the following Figs. 11 and 12. In Fig. 11 , at t = 1 (∼ 3 hours) we note that a large cluster of cells is formed at the leading edge of the primary tumour, while by t = 10 (1 day) this invading leading edge of the cancer cells has migrated further into the tissue driven mainly by haptotaxis. As time evolves, t = 25 (∼ 3 days), and the invading leading group of cancer cells migrates further into the domain, a new group of cells starts to form just behind the invading leading front as a result of increased cancer cell proliferation due to uPA-cancer binding mediated signal transduction pathways. By t = 35 (∼ 4 days) we note that three cluster of cancer cells have formed, while by t = 55 (∼ 6.5 days) the number of groups of cells eventually increases to four. By t = 60 (∼ 7 days), in Fig. 12 we note the formation of five distinct clusters of cancer cells, while as time evolves, t = 105 (∼ 12 days) each cluster of cells start to migrate mainly due to the chemotactic response of the cancer cells to the PAI-1 concentration gradients. By t = 125 (∼ 14.5 days) we observe three remaining clusters of cells, while additionally by t = 155 (∼ 18 days) the number of clusters of cells has reduced to two. However, by t = 175 (∼ 20 days), we have an increase in the number of clusters of cells to four. Once again, this dynamic behaviour of the system appears to persist indefinitely.
In the final set of figures in this section, we consider a set of parameter values where the binding rates of uPA, PAI-1 and VN to be similar, and solve system (12) In Fig. 13 we note that at t = 1 (∼ 3 hours), a large cluster of cells has built up at the leading edge of the primary tumour. However, by t = 10 (∼ 1 day) due to the "taxis" competition between uPA, PAI-1-mediated and VN-mediated chemotaxis and haptotaxis respectively cancer cells are unable to migrate further into the region. As time evolves, by t = 55 (6 days) a large region of the extracellular matrix has been degraded as a result of uPA secretion by the cancer cells. By t = 60 (∼ 7 days), in mentioned results, we once again note the cancer cells' variability, and the ability of the primary tumour to produce several different distinct masses of cells heterogeneously distributed in space. Surpisingly, at t = 155 (∼ 18 days), in Fig. 15 we point out regions of extracellular matrix redistribution which cancer cells degrade locally through the uPA production and consequently plasmin activation. As time evolves, t = 250 (29 days), the tumour heterogeneity is even more observable as a result of increased abnormal cell proliferation.
Discussion
In this paper we have presented a mathematical model of the invasion of tissue by cancer cells through the secretion of matrix degrading enzymes. In this regard, the model focuses specifically on the role of the urokinase plasminogen activation system. The model is more complex than previous mathematical models of invasion (cf. Refs. 58, 59 and 7), but in our opinion is more faithful to the key biological components of tissue invasion through its incorporation of the major components of the uPA activation system. The main achievement of this model is that fairly simple mathematical models representing the binding interactions of the components of the plasminogen activation system coupled with cell migration were able to capture the main characteristic effects of the system in cancer progression and invasion. The results of the simulations of the model show a very rich dynamic spatio-temporal behaviour. The observed spatio-temporal heterogeneities in the solution profiles arise from the complex interplay between proliferative effectscancer cell proliferation and matrix re-modelling -and gradient-driven migration (chemotaxis and haptotaxis). Cancer cells initially degrade the matrix through the uPA system (ultimately via plasmin activation) and can initially move via taxis into the degraded matrix, coupled with cell proliferation. However, as the matrix remodels, this provides the cancer cells with the opportunity to "re-degrade" this re-modelled matrix with the consequence that multiple clusters of invading cancer cells appear throughout the domain. While high levels of the inhibitor PAI-1 halt invasion at the beginning, as time evolves clusters of cancer cells in distinct spatial locations form. Therefore, as Blasi 20 has verified, the uPA receptors (uPAR) can act at a distance, through either cell to cell contact or by releasing a migratory signal. In this regard, we could assume that the uPA/uPAR recycling term that we included may be responsible for the formation of distant and distinct clusters of cells. In regions of high PAI-1, uPAR may use uPA as a "bait" to bind to PAI-1 and then internalize the uPA/uPAR/PAI-1 and recycle back for new rounds of migration.
The results of the model have shown that the spatially heterogeneous distributions of cancer cells which arise as a consequence of simple binding reactions and gradient-driven migration may help to explain certain clinically and experimentally observed phenomena in carcinoma and multicellular spheroids, i.e. the heterogeneous "anarchic" spatial distribution of proliferating cancer cells and tissue. The applications of our complete plasmin taxis-reaction-diffusion equations to cancer invasion enable us to model more realistically solid tumour invasion of tissue and we believe that the results of the numerical simulations are highly consistent with in vitro as well as in vivo experimentally observed proliferative heterogeneity of cancer cells in solid tumours at their invasive stage. The results of our models are in line with recent experimental results, that show that when breast cells become malignant, plasmin is activated on their membrane and their morphology is changed from sheet-like structures to multicellular heterogeneous masses. 34 Considering these reports, one may speculate that through the activation of plasmin on their membrane, micrometastatic tumour cells form multicellular clusters and thus manage to shield themselves from the action of chemotherapeutic drugs, thereby impeding chemotherapies and raising therapeutic drug doses to prohibitively high levels. In this regard, compromising the protective shield or even targeting plasmin with its α 2 -antiplasmin inhibitor may be a reasonable target of new therapeutic designs for cancer therapies.
Concerning the mathematical aspect of the results of the model, we note that similar spatio-temporal behaviour has been observed but in systems with limit-cycle kinetics (cf. Refs. 81 and 82) . This is not the case here. An analysis of the steady states of the model 79 reveals that there are no limit-cycles present in the kinetic equations of our system. The dynamic, heterogeneous spatio-temporal behaviour of the system is therefore due to the interplay between proliferation, matrix degradation and taxis of the cells, as described above.
Of course, the results we have presented in this paper are for a specific set of parameters. Other interesting dynamic spatio-temporal behaviour is observed for other ranges of the parameters and for other aspects of the model e.g. travelling wave-like behaviour. This is explored in great depth in Lolas.
79 For example, considering a simpler "sub-model" of our system, where we assume interaction only between cancer cells, tissue and uPA: with the discrete modelling approach of Refs. 6 and 7. This raises the challenging mathematical question of linking different biological scales and how to model this, a topic which is addressed in the very interesting paper of Lachowicz.
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